{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"69.6","upperLimit":"91.5","value":"82.5"},{"groupId":"OG001","lowerLimit":"43.6","upperLimit":"92.1","value":"72.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"Percent of patients with objective response defined as partial response or better based on the International Myeloma Working Group Response (IMWG) criteria","dispersionType":"90% Confidence Interval","groups":[{"description":"•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \\& 15 Cycles 3-8\n\nOther Name: HuLuc63\n\n•Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24\n\nOther Name: REVLIMID\n\n•Drug: Dexamethasone 40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8\n\nOther Name: Decadron\n\nElotuzumab: 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \\& 15 Cycles 3-8\n\nLenalidomide: 25 mg Oral; Days 1-21 days Cycles 1-24\n\nDexamethasone: 40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8","id":"OG000","title":"Elo / Len / Dex"},{"description":"•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \\& 15 Cycles 3-8\n\nOther Name: HuLuc63\n\n•Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24\n\nOther Name: REVLIMID\n\nElotuzumab: 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \\& 15 Cycles 3-8\n\nLenalidomide: 25 mg Oral; Days 1-21 days Cycles 1-24","id":"OG001","title":"Elo / Len"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 Years from start of treatment","title":"Objective Response Percent","type":"SECONDARY","unitOfMeasure":"percentage of participants"}